Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hanhee | - |
dc.contributor.author | Shim, Man Kyu | - |
dc.contributor.author | Yang, Suah | - |
dc.contributor.author | Song, Sukyung | - |
dc.contributor.author | Moon, Yujeong | - |
dc.contributor.author | Kim, Jinseong | - |
dc.contributor.author | Byun, Youngro | - |
dc.contributor.author | Ahn, Cheol-Hee | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.date.accessioned | 2022-04-28T19:40:26Z | - |
dc.date.available | 2022-04-28T19:40:26Z | - |
dc.date.created | 2022-04-28 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/140475 | - |
dc.description.abstract | Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | DRUG-DELIVERY | - |
dc.title | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kwangmeyung | - |
dc.identifier.doi | 10.3390/pharmaceutics14010083 | - |
dc.identifier.scopusid | 2-s2.0-85122136284 | - |
dc.identifier.wosid | 000746970700001 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.14, no.1 | - |
dc.relation.isPartOf | PHARMACEUTICS | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordAuthor | prodrug | - |
dc.subject.keywordAuthor | albumin | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | targeted therapy | - |
dc.subject.keywordAuthor | chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.